S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$13.79
+0.31 (+2.30 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.00
Now: $13.79
$13.83
50-Day Range
$12.89
MA: $14.35
$15.41
52-Week Range
$6.25
Now: $13.79
$16.13
Volume1.55 million shs
Average Volume2.96 million shs
Market Capitalization$3.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
Amicus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$182.24 million
Book Value$1.87 per share

Profitability

Net Income$-356,390,000.00
Net Margins-129.10%

Miscellaneous

Employees508
Market Cap$3.57 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$13.79
+0.31 (+2.30 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

How has Amicus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 71.3% and is now trading at $13.79.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amicus Therapeutics
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. The biopharmaceutical company had revenue of $62.35 million for the quarter, compared to analysts' expectations of $62.66 million. Amicus Therapeutics had a negative return on equity of 65.53% and a negative net margin of 129.10%.
View Amicus Therapeutics' earnings history
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Monday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $254.82 million.

What price target have analysts set for FOLD?

9 equities research analysts have issued 1 year price objectives for Amicus Therapeutics' stock. Their forecasts range from $12.50 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $20.28 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (gild), Sangamo Therapeutics (sgmo), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Micron Technology (MU).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 52)
  • Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
  • Dr. Jay A. Barth, Chief Medical Officer (Age 55)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.32%), FMR LLC (3.07%), Jennison Associates LLC (1.97%), Victory Capital Management Inc. (1.36%), Nuveen Asset Management LLC (1.12%) and Goldman Sachs Group Inc. (1.04%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc, Samantha Prout and William D Baird III.
View institutional ownership trends for Amicus Therapeutics
.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Point72 Asset Management L.P., Goldman Sachs Group Inc., Phoenix Holdings Ltd., Victory Capital Management Inc., Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., and Nuveen Asset Management LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., SG Americas Securities LLC, Man Group plc, Essex Investment Management Co. LLC, Silvercrest Asset Management Group LLC, and Fairmount Funds Management LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Amicus Therapeutics
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $13.79.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $3.57 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.